Cargando…

Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data

AIM: Immune checkpoint inhibitors (ICIs) are a cornerstone in cancer treatment but they can induce immune-related adverse events (irAEs). Furthermore, patients with pre-existing autoimmune and/or inflammatory disease (AID) have been excluded from clinical trials. The objective of this study is to ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calvo, Virginia, Fernández, Marta Andrés, Collazo-Lorduy, Ana, Franco, Fernando, Núñez, Beatriz, Provencio, Mariano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656306/ https://www.ncbi.nlm.nih.gov/pubmed/34899991 http://dx.doi.org/10.2217/lmt-2021-0003

Ejemplares similares

Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma
por: Blanco, Mariola, et al.
Publicado: (2022)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022)

Immune checkpoint inhibitors for patients with pre-existing autoimmune diseases
por: Maeda, Osamu
Publicado: (2023)

Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review
por: Ortega-Franco, Ana, et al.
Publicado: (2020)

P31.03 The Impact of the COVID-19 Pandemic on a Thoracic Tumor Unit of a Tertiary Hospital in Spain
por: Cudero, L., et al.
Publicado: (2021)

Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease
por: Alexander, Swetha, et al.
Publicado: (2021)

To burn-out or not to burn-out: a cross-sectional study in healthcare professionals in Spain during COVID-19 pandemic
por: Torrente, Maria, et al.
Publicado: (2021)

Examining explainable clinical decision support systems with think aloud protocols
por: Anjara, Sabrina G., et al.
Publicado: (2023)

Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy
por: Lusa, Amanda, et al.
Publicado: (2022)

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
por: Arora, Sanjeevani, et al.
Publicado: (2019)

Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
por: Lopez-Olivo, Maria A., et al.
Publicado: (2023)

A real‐world data of Immune checkpoint inhibitors in solid tumors from India
por: Noronha, Vanita, et al.
Publicado: (2021)

Long-term follow up of Hodgkin lymphoma
por: Perez-Callejo, David, et al.
Publicado: (2018)

Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
por: Boland, Patrick, et al.
Publicado: (2020)

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
por: Martinez Chanza, Nieves, et al.
Publicado: (2020)

Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study
por: Lopez-Olivo, Maria A., et al.
Publicado: (2023)

1733P Real-world data: Cancer and SARS-CoV-2 infection
por: Nunez Garcia, B., et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
por: Calvo, Virginia, et al.
Publicado: (2021)

Cancer and SARS-CoV-2 Infection: A Third-Level Hospital Experience
por: Calvo, Virginia, et al.
Publicado: (2021)

Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
por: Kanjanapan, Yada, et al.
Publicado: (2023)

Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
por: Crittenden, Marka R., et al.
Publicado: (2018)

Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy
por: Gupta, Vineet Govinda, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
por: Chen, Xue, et al.
Publicado: (2022)

An Artificial Intelligence-Based Tool for Data Analysis and Prognosis in Cancer Patients: Results from the Clarify Study
por: Torrente, María, et al.
Publicado: (2022)

Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2020)

Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
por: Provencio, Mariano, et al.
Publicado: (2022)

Transient Thyroiditis Followed by Exacerbation of Hypothyroidism After Immune Checkpoint Inhibitor Therapy (Nivolumab and Ipilimumab) in a Patient With Pre-existing Autoimmune Hypothyroidism: A Case Report
por: Hayakawa, Guy, et al.
Publicado: (2023)

Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy
por: Lee, Charlotte, et al.
Publicado: (2022)

Real-world management of juvenile autoimmune liver disease
por: de Boer, Y S, et al.
Publicado: (2018)

Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Patterns and outcome of unplanned care in lung cancer patients: an observational study in a medical oncology department
por: Sánchez, Juan C., et al.
Publicado: (2023)

EP06.01-017 Clinical Impact of SARS-CoV2 Pandemic in the Diagnosis of Early-Stage Thoracic Tumours
por: Garitaonaindía Díaz, Y., et al.
Publicado: (2022)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia
por: Al Nuhait, Mohammed, et al.
Publicado: (2021)

Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry
por: Jacob, Aasems, et al.
Publicado: (2021)

The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman
por: Salman, Bushra, et al.
Publicado: (2023)

Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
por: von Itzstein, Mitchell S., et al.
Publicado: (2022)

Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico
por: Jaime-Pérez, José Carlos, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1ca4ga9h4q1o0vs1846842ptjd